Recent 8-K filings for CVSI
Highest-materiality recent filing
CV Sciences agrees to acquire Extract Labs for $1.4M cash and stock, plus earnout
- Total consideration: $400K cash + $1M in CVSI stock at closing; up to $600K earnout in stock.
- Earnout tied to Extract Labs revenue targets: $3.5M-$4.6M per 12-month period for two years.
-
CV Sciences shareholders reject reverse stock split; three directors elected
Proposal 2 (reverse stock split up to 1-for-800) failed: 48.5M for, 59.6M against, 8.1M abstain.
-
CV Sciences FY2025 revenue down 12% to $13.8M; adjusted EBITDA loss narrows to $0.3M
Revenue $13.8M for FY2025 vs $15.7M in 2024, a 12.2% decline on lower volume and regulatory headwinds.
-
CV Sciences restructures notes: adds conversion at $0.06/share, principal to $2.256M
Outstanding note principal increased 20% to $2,256,000; monthly redemption obligation eliminated.
-
Revenue $3.3M, down 16% YoY from $3.9M; net revenue from products launched since Jan 2023 contributed 39%.
-
CV Sciences issues $600K secured note with $300K net proceeds; potential add'l $750K
Issued $600K secured promissory note with 25% OID ($150K) plus $150K modification fee; net proceeds $300K.
-
CV Sciences amends $1.6M secured note, extends maturity to 2027, defers payments
Original $1.6M note issued Feb 2025 with $400K OID; outstanding balance $1.28M after $320K payments.
-
CV Sciences Q2 revenue $3.6M (-8% YoY); first positive adjusted EBITDA in six years
Revenue $3.6M, down 8% from $4.0M in Q2 2024; units sold down 7%, avg price down 2.8%.
-
CV Sciences FY2024 revenue $15.7M (-1.9% YoY), operating loss $2.2M vs income $3.4M in 2023
Revenue $15.7M vs $16.0M in 2023; Q4 revenue $3.9M (+2.2% YoY).
-
CV Sciences initiates arbitration against former legal counsel Procopio over faulty RSU tax advice
Arbitration filed Feb 12, 2025; claims Procopio provided incorrect tax advice on CEO Mona's RSU settlement.
-
CV Sciences disputes Extract Labs acquisition termination by Sellers; evaluating options
On Feb 5, 2025, Extract Labs owners informed CV Sciences they cannot close due to alleged failure to obtain bank consent, purportedly terminating the Stock Purchase Agreement.
-
CV Sciences agrees to acquire Extract Labs for $1.4M cash and stock, plus earnout
Total consideration: $400K cash + $1M in CVSI stock at closing; up to $600K earnout in stock.
-
Revenue $4.0M flat YoY and sequentially; B2C sales up 4% offset by B2B decline of 3%.
-
CV Sciences acquires Elevated Softgels for up to $1M; plans in-sourcing of +PlusCBD production
Total consideration up to $1,000,000: $100k cash, 17.4M shares ($700k), plus earnout up to $200k.
-
CV Sciences Q1 2024 revenue $4.0M, gross margin 46.3%, operating loss $0.6M
Revenue $4.0M, down 4% YoY from $4.1M, up sequentially from $3.8M in Q4 2023.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.75 · Median 0.60 · Most common event earnings